| [1] |
Cardoso C, Mignon C, Hetet G, et al. The human EZH2 gene: genomic organisation and revised mapping in 7q35 within the critical region for malignant myeloid disorders[J]. Eur J Hum Genet, 2000, 8(3): 174-80.
|
| [2] |
Viréd E, Brenner C, Deplus R, et al. The Polycomb group protein EZH2 directly controls DNA methylation[J]. Nature, 2006, 43 9(7078): 871-4.
|
| [3] |
Cao R, Wang L, Wang H, et al. Role of histone H3 lysine 27 methylation in polycomb-group silencing[J]. Science, 2002, 29 8(5595): 1039-43.
|
| [4] |
Studo T, Utsunomiya T, Mimori K, et al. Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma[J]. Br J Cancer, 2005, 92(9): 1754-8.
|
| [5] |
Sasaki M, Ikeda H, Itatsu K, et al. The overexpression of polycomb group proteins Bmi1 and EZH2 is associated with the progression and aggressive biological behavior of hepatocellular carcinoma[J]. Lab Invest, 2008, 88(8): 873-82.
|
| [6] |
Bryant RJ, Cross NA, Eaton CL, et al. EZH2 promotes proliferation and invasiveness of prostate cancer cells[J]. Prostate, 2007, 67(5): 54 7-56.
|
| [7] |
Debeb BG, Gong Y, Atkinson RL, et al. EZH2 Expression correlates with locoregional recurrence after radiation in inflammatory breast cancer[J]. J Exp Clin Cancer Res, 2014, 33: 58.
|
| [8] |
Liu Y, Liu T, Bao X, et al. Increased EZH2 expression is associated with proliferation and progression of cervical cancer and indicates a poor prognosis[J]. Int J Gynecol Pathol, 2014, 33(3): 218-24.
|
| [9] |
Yoo KH, Hennighausen L. EZH2 Methylation and H3K27 methylation in breast cancer[J]. Int J Biol Sci, 2012, 8(1): 59-65.
|
| [10] |
Ma R, Wei Y, Huang X, et al. Inhibition of GSK3β activity is associated with excessive EZH2 expression and enhanced tumor invasion in nasopharyngeal carcinoma[J]. PLos One, 2013, 8(7): e68614.
|
| [11] |
Eskander RN, Ji T, Huynh B, et al. Inhibition of enhancer of zeste homolog 2 (EZH2) expression is associated with decreased tumor cell proliferation, migration, and invasion in endometrial cancer cell lines[J]. Int J Gynecol Cancer, 2013, 23(6): 997-1005.
|
| [12] |
Cai MY, Hou JH, Rao HL, et al. High expression of H3K27me3 in human hepatocellular carcinomas correlates closely with vascular invasion and predicts worse prognosis in patients[J]. Mol Med, 20 11, 17(1-2): 12-20.
|
| [13] |
Ngollo M, Lebert A, Dagdemir A, et al. The association between Histone 3 Lysine 27 Trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters [J]. BMC Cancer, 2014, 14: 994.
|
| [14] |
Benard A, Goossens-Beumer IJ, van Hoesel AQ, et al. Prognostic value of polycomb proteins EZH2, BMI1 and SUZ12 and histone modification H3K27me3 in colorectal cancer[J]. PLos One, 2014, 9( 9): e108265.
|
| [15] |
Cai MY, Tong ZT, Zhu W, et al. H3K27me3 protein is a promising predictive biomarker of patients’ survival and chemoradioresistance in human nasopharyngeal carcinoma[J]. Mol Med, 2011, 17(11-12): 1137-45.
|
| [16] |
He LJ, Cai MY, Xu GL, et al. Prognostic significance of overexpression of EZH2 and H3K27me3 proteins in gastric cancer [J]. Asian Pac J Cancer Prev, 2012, 13(7): 3173-8.
|
下载:
